Comparative Effectiveness of Switching From First-Generation Basal Insulin to Glargine 300 U/ml or Degludec 100 U/ml in Type 1 Diabetes: The RESTORE-1 Study
出版年份 2020 全文链接
标题
Comparative Effectiveness of Switching From First-Generation Basal Insulin to Glargine 300 U/ml or Degludec 100 U/ml in Type 1 Diabetes: The RESTORE-1 Study
作者
关键词
-
出版物
Diabetes Therapy
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-12-22
DOI
10.1007/s13300-020-00982-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Lower risk of severe hypoglycaemia with insulin glargine 300 U/ mL versus glargine 100 U/ mL in participants with type 1 diabetes: A meta‐analysis of 6‐month phase 3 clinical trials
- (2020) Thomas Danne et al. DIABETES OBESITY & METABOLISM
- Switching Patients with Type 1 Diabetes to Insulin Degludec from Other Basal Insulins: Real-World Data of Effectiveness and Safety
- (2019) Paola Ponzani et al. Diabetes Therapy
- 6. Glycemic Targets: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- The importance of the initial period of basal insulin titration in people with diabetes
- (2019) Kamlesh Khunti et al. DIABETES OBESITY & METABOLISM
- Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes
- (2018) T.S. Bailey et al. DIABETES & METABOLISM
- Insulin therapy, weight gain and prognosis
- (2018) Israel Hodish DIABETES OBESITY & METABOLISM
- Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin
- (2018) Fang Liz Zhou et al. DIABETES OBESITY & METABOLISM
- More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial
- (2018) Julio Rosenstock et al. DIABETES CARE
- Good Practices for Real‐World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR‐ISPE Special Task Force on Real‐World Evidence in Health Care Decision Making
- (2017) Marc L. Berger et al. VALUE IN HEALTH
- Glucose Variability: Timing, Risk Analysis, and Relationship to Hypoglycemia in Diabetes
- (2016) Boris Kovatchev et al. DIABETES CARE
- Gender-Disparities in Adults with Type 1 Diabetes: More Than a Quality of Care Issue. A Cross-Sectional Observational Study from the AMD Annals Initiative
- (2016) Valeria Manicardi et al. PLoS One
- New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)
- (2015) Philip D. Home et al. DIABETES CARE
- Low within- and between-day variability in exposure to new insulin glargine 300 U/ml
- (2015) R. H. A. Becker et al. DIABETES OBESITY & METABOLISM
- New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)
- (2015) G. B. Bolli et al. DIABETES OBESITY & METABOLISM
- Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine
- (2015) Tim Heise et al. Expert Opinion on Drug Metabolism & Toxicology
- New forms of insulin and insulin therapies for the treatment of type 2 diabetes
- (2015) Avivit Cahn et al. Lancet Diabetes & Endocrinology
- Trends over 8 years in quality of diabetes care: results of the AMD Annals continuous quality improvement initiative
- (2014) Maria Chiara Rossi et al. ACTA DIABETOLOGICA
- New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)
- (2014) Matthew C. Riddle et al. DIABETES CARE
- New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)
- (2014) Hannele Yki-Järvinen et al. DIABETES CARE
- The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes
- (2013) L. Meneghini et al. DIABETES CARE
- Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes
- (2013) Stephen C.L. Gough et al. DIABETES CARE
- Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension
- (2013) Chantal Mathieu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)
- (2012) B. Zinman et al. DIABETES CARE
- Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes
- (2012) T. Heise et al. DIABETES OBESITY & METABOLISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started